Browse by author
Lookup NU author(s): Professor Farhad Kamali
Full text for this publication is not currently held within this repository. Alternative links are provided below where available.
Vernalis is developing V-10153, a recombinant plasminogen activator stimulator, for the potential treatment of thrombotic disorders and cardiovascular disease. By March 2004, a phase II trial in acute myocardial infarction had been completed, and by July 2005, Vernalis intended to initiate a phase II trial in stroke later that same year. © The Thomson Corporation.
Author(s): Kamali F
Publication type: Review
Publication status: Published
Journal: Current Opinion in Investigational Drugs
ISSN (print): 1472-4472
ISSN (electronic): 2040-3429
PubMed id: 16187695